INBRAIN Neuroelectronics vs Karius
Side-by-side comparison of AI visibility scores, market position, and capabilities
INBRAIN Neuroelectronics develops graphene-based brain-computer interfaces for AI-driven, adaptive neuromodulation; raised €30M Series B in 2024; targeting Parkinson's, epilepsy, and psychiatric disorders;
About
INBRAIN Neuroelectronics is a neurotechnology company founded in 2019 as a spin-out from the Catalan Institute of Nanoscience and Nanotechnology (ICN2) in Barcelona, Spain. The company develops minimally invasive brain-computer interfaces built on graphene — a single layer of carbon atoms with exceptional electrical conductivity, biocompatibility, and transparency to MRI imaging. INBRAIN's graphene electrodes enable higher spatial resolution neural sensing and more precise, adaptive stimulation than conventional metal electrodes used in implantable neurostimulators.
Karius raised $409M total including a $100M Series C in May 2024; its genomic blood test detects 1,000+ pathogens at 400+ U.S. hospitals; launched Karius Focus BAL for pneumonia in April 2025.
About
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens (bacteria, fungi, viruses, parasites) in seriously ill patients. The test is used when conventional cultures and targeted diagnostics fail, providing clinicians at transplant centers, children''s hospitals, and ICUs with a comprehensive pathogen report within 24 hours.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.